AI Article Synopsis
Article Abstract
Purpose: Breast cancer is the most common malignancy in Brazilian women, with 66,280 new cases in 2020 (with 20% overexpressing human epidermal growth factor receptor 2 [HER2]). The trastuzumab biosimilar was the first oncology biosimilar approved in Brazil for HER2-positive breast cancer treatment. This study aimed to assess the current level of knowledge of biosimilars, comfort of use, extrapolation indications, and switching of practices among oncologists in Brazil.
Methods: A 24-question survey was developed using an online platform that sought information regarding responders' characteristics and use of biosimilars. The survey analyzed the basic knowledge of biosimilars, trastuzumab biosimilars, level of comfort with extrapolation, switching treatment regimens, and opinions concerning the cost of HER2-positive breast cancer therapy. Data were collected between July and September 2019 and included 144 oncologists from five Brazilian regions.
Results: In total, 95% of respondents could identify the most appropriate definition of biosimilars and 96% felt comfortable prescribing trastuzumab biosimilars. Although 63% of respondents would use the biosimilar in all settings wherein the reference biologic was approved, 35% would use the biosimilar for cases involving metastatic disease. Although 82% of oncologists were in favor of switching from a reference biologic to a biosimilar, 18% would avoid switching regimens. The lack of studies detailing switching to other regimens and the correct timing to switch was the major concern. The cost of HER2 therapy was a significant concern for most oncologists.
Conclusion: Oncologists demonstrated a high level of knowledge of biosimilars and encouraging levels of prescriber use; however, extrapolation and switching treatment regimens are barriers to the effective use of biosimilars in cancer treatment. Efforts should be concentrated on strategies involving medical education programs on biosimilars.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457873 | PMC |
| http://dx.doi.org/10.1200/GO.20.00649 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Re: Simulating the healthcare workforce impact and capacity for pancreatic cancer care in Victoria: a model-based analysis.
ANZ J Surg
December 2024
Department of General Surgical Specialities, Royal Melbourne Hospital, Melbourne, Australia.
Superiority of Pathologic Lymph Node Ratio over Positive Lymph Node Count in Operated Early-Stage Breast Cancer.
Ann Ital Chir
December 2024
Department of General Surgery, Faculty of Medicine, Dicle University, 21280 Diyarbakır, Türkiye.
Aim: In early-stage breast cancer, the axillary lymph nodes play a crucial role in determining the prognosis of the disease. The rate of lymph node involvement might be a more valuable prognostic factor than the number of positive lymph nodes. Therefore, we aimed to evaluate whether the lymph node ratio (LNR) is a superior prognostic indicator compared to the pathologic lymph node count in early-stage disease.
View Article and Find Full Text PDFClinicopathologic Characteristics of Breast Cancer Patients Who Had a Pathologic Complete Response after Neoadjuvant Treatment.
Ann Ital Chir
December 2024
Department of General Surgery, Izmir Katip Celebi University, Atatürk Education and Research Hospital, 35620 Izmir, Turkey.
Aim: Breast cancer is the most common cancer in women and is a leading cause of cancer-related mortality. The role of neoadjuvant therapy (NAT) in conjunction with surgical intervention is becoming increasingly prominent in the field of oncology. NAT enhance the probability of breast-conserving surgery in cases of locally advanced breast cancer and in patients with metastatic or inoperable disease.
View Article and Find Full Text PDFPrognostic Factors, Predictive Modeling, and Treatment Patterns in Breast Cancer Patients with Bone Metastasis Receiving First-Line Chemotherapy: A Population-Based Study.
Ann Ital Chir
December 2024
The Orthopedics Department, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, 321000 Jinhua, Zhejiang, China.
Aim: The prognostic factors and a nomogram applicable to breast cancer (BC) patients with bone metastasis (BM) who received first-line chemotherapy have not been extensively studied. This study aimed to identify prognostic factors and construct a prognostic nomogram to predict overall survival (OS) in this population.
Methods: Data for BC patients with BM undergoing first-line chemotherapy were retrieved from the Surveillance, Epidemiology, and End Results (SEER) database from 2010 to 2016.
Proliferative Myositis of the Breast in a Patient with Contralateral Phyllodes Tumor: A Unique Pseudomalignant Lesion.
Ann Ital Chir
December 2024
Department of Pathology, Bakirkoy Dr. Sadi Konuk Education and Research Hospital, 34147 İstanbul, Türkiye.
Aim: We report a case of proliferative myositis (PM) of the breast, which is the second reported in the English literature.
Case Presentation: A 49-year-old woman underwent surgery due to a fibroadenoma in the right and phyllodes tumor in the left breast. One month after these surgeries, a right breast mass rapidly grew at the surgical site, and biopsy did not provide a diagnosis.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!